

Published in final edited form as:

Biochem Pharmacol. 2005 April 15; 69(8): 1215–1223. doi:10.1016/j.bcp.2005.01.018.

Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress

Smadar Yitzhaki^a, Vladimir Shneyvays^a, Kenneth A. Jacobson^b, and Asher Shainberg^{a,*}

^aFaculty of Life Sciences, Bar-Ilan University, Ramat-Gan 52900, Israel

^bLaboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA

Abstract

Cardiomyocytes express one or more subtypes of P2 receptors for extracellular nucleotides. P2 purinoceptors, which are activated by nucleotides, are classified as P2X or P2Y: P2X receptors are ligand-gated intrinsic ion channels, and P2Y receptors are G protein-coupled receptors. Extracellular pyrimidine and purine nucleotides are released from the heart during hypoxia. Although the cardioprotective effects of purines acting via purinoceptors were studied intensively, the physiological role of uracil nucleotide-responsive P2Y₂, P2Y₄, P2Y₆, and P2Y₁₄ receptors is still unclear, especially in the cardiovascular system. This study revealed that uridine-5'-triphosphate (UTP) protected cultured rat cardiomyocytes during hypoxia and explored the UTP signaling pathway leading to this cardioprotection. We found that UTP, but not UDP or uridine, significantly reduced cardiomyocyte death induced by hypoxia. Incubation with UTP for 1 h, before exposure to hypoxic conditions, protected the cells 24 h later. The cardioprotective effect of UTP was reduced in the presence of the P2 antagonist suramin. In addition, UTP caused a transient increase of [Ca²⁺]_i in cardiomyocytes. Pyridoxal-5'-phosphate-6-azophenyl-2,4-disulfonate (PPADS) or Reactive blue 2 (RB-2), other antagonists of P2 receptors, abolished the [Ca²⁺]_i elevation caused by UTP. We used various inhibitors of the Ca²⁺ signaling pathway to show that UTP elevated levels of [Ca²⁺]_i, originating from intracellular sources, via activation of phospholipase C and the IP₃ receptor. Interestingly, these inhibitors of the Ca²⁺ signaling pathway did not prevent the immediate protective effect caused by UTP. Although mitochondrial K_{ATP} channels are involved in other preconditioning mediator pathways, the involvement of these channels in the cardioprotective effect induced by UTP was ruled out, because 5-hydroxydecanoic acid (5-HD), a specific inhibitor of these channels, did not prevent the protection.

Keywords

P2Y₂ nucleotide receptor; G protein-coupled receptor; Pyrimidines; Cardioprotection; Ischemia; Preconditioning

1. Introduction

Myocardial infarction and heart failure are leading causes of morbidity and mortality in humans. Considerable effort has been devoted to improving functional recovery and reducing the extent of infarction after ischemic episodes. A step in this direction was the discovery that the heart is significantly protected against ischemic injury when first preconditioned by a brief ischemia [1]. Adenosine, a metabolite of adenine nucleotides, simulates the protection afforded by preconditioning (PC) via A₁ and A₃ receptors.

However, accumulating evidence suggests that adenosine receptors are not the only mediators of PC [2-4], but that adrenoceptors [5], bradykinin receptors [6], opioid receptors [7], and ATP receptors [8] may also contribute to PC.

Purine and pyrimidine nucleotides have widespread and specific extracellular signaling actions in the regulation of a variety of functions in many tissues. In 1978 Burnstock proposed that specific receptors for extracellular nucleosides (P1) or nucleotides (P2) mediate the physiological effects of adenosine and ATP, respectively [9]. According to pharmacological evidence, mechanisms of signal transduction, and molecular structure, receptors that mediate the extracellular actions of purine and pyrimidine nucleotides are divided into two major families: ligand-gated receptors (P2X) and G protein-coupled receptors (P2Y). In contrast to P2X receptors, the class of P2Y receptors is activated not only by ATP and its derivatives, but also by other naturally occurring nucleotides. The P2Y₂ and P2Y₄ receptors are activated by the uracil nucleotide UTP (uridine-5'-triphosphate) acting as an autocrine regulator [10,11]. These receptors are preferentially coupled to G_q and therefore activate phospholipase C_β, leading to the formation of inositol trisphosphate, Ca²⁺ elevation, and production of diacylglycerol, which activates protein kinase C (PKC) and mitogen-activated protein kinases [12,13]. Thus, activation of P2Y₂ and P2Y₄ receptors and subsequently kinases can have long-term, tropic effects on cardiomyocyte activity.

Whereas the effects of purine nucleosides and nucleotides in myocardial infarction and ischemia have been intensively studied [14], the role of pyrimidine nucleotides under hypoxic conditions has not been well explored. Our principal aim was to elucidate the protective effects of UTP and pyrimidineric receptor activation against detrimental factors of ischemia/hypoxia. For this reason we sought to explore whether P2Y₂ and P2Y₄ receptors are present on the surface of cultured newborn rat cardiomyocytes and the expression levels of these receptors. Receptor functionality was demonstrated by evaluation of the calcium response following receptor activation and by the initiation of signal transduction pathways, which resulted in attenuating cardiomyocyte injury in hypoxia. For this purpose we studied the expression and localization of P2Y₂ and P2Y₄ receptor proteins in cultured cardiomyocytes through immunohistochemistry and Western blotting. Changes in intracellular Ca²⁺ concentration ([Ca²⁺]_i) after the application of nucleotides were studied by indo-1 cytofluorometry. Morphological evaluation of cultured cells, measurement of lactate dehydrogenase (LDH) release to the culture medium, and determination of ATP content were used to characterize the protection from hypoxic damage upon UTP receptor activation.

The present study provides evidence for the first time that the extracellular pyrimidine nucleotide, UTP, could play a substantial role in mediating cardioprotection from hypoxic damage through specific receptors.

2. Experimental procedures

2.1. Cell culture

Rat hearts (2–3 d old) were removed under sterile conditions and washed three times in PBS to remove excess blood cells. The hearts were minced and then gently agitated in RDB, a solution of proteolytic enzymes (Life Science Research Inst. [15]), prepared from a fig tree extract. After treatment with RDB, cell viability was found to be 98%, in contrast to 85% in trypsin-treated monolayer cultures. The RDB was diluted 1:100 in Ca²⁺- and Mg²⁺-free PBS at 25 °C for a few cycles of 10 min each, as described previously [16]. Dulbecco's modified Eagle's medium, supplemented with inactivated 10% horse serum (Biological Industries) and 0.5% chick embryo extract, was added to supernatant suspensions containing dissociated cells. The mixture was centrifuged at 300 × g for 5 min. The supernatant phase

was discarded, and the cells were resuspended in the same medium. The suspension of the cells was diluted to 1.0×10^6 cells/ml, and 1.5 ml of the suspension was placed in 35-mm plastic culture dishes on collagen/gelatin-coated coverglasses. The cultures were incubated in a humidified atmosphere of 5% CO₂, 95% air at 37 °C. Confluent monolayers exhibiting spontaneous contractions were developed in culture within 2 d. All experiments were performed between days 5 and 7 in culture.

2.2. [Ca²⁺]_i measurements

Intracellular free calcium ion concentration was estimated from indo-1 fluorescence with the ratio method (the SAMPLE program) described elsewhere [17,18].

2.3. Hypoxic conditions

Myocyte cultures 5–7 d old were washed from the medium with glucose-free PBS containing 5 μM HEPES at pH 7.4 before exposing the myocytes to the various conditions at 37 °C. The hypoxic condition consisted of 120 min in a hypoxic incubator in which the atmosphere was replaced by the inert gas argon (100%) in glucose-free media [16,19]. The hypoxic damage was characterized at the end of the hypoxic period by morphological and biochemical evaluation. Continuous monitoring of [Ca²⁺]_i during hypoxia was realized in a special barrier well, where cells were protected from oxygen by a laminar counterflowing layer of argon gas as previously described [20]. The coverglasses with cultured cells were placed at the bottom of the well. This chamber was mounted on a specially modified Zeiss inverted epifluorescence microscope.

2.4. Assays of intracellular ATP level

After hypoxia, control and experimental cells were harvested in 1 ml cold 5% trichloroacetic acid. The cell extract was used for the measurement of ATP content with the luciferin–luciferase bioluminescence kit (CLSII, Boehringer) following the manufacturer's protocol. The values are expressed as nmol/mg of protein [17].

2.5. Experiments with purinergic and pyrimidinergic ligands

UTP at concentrations of 3–50 μM was applied to the cell cultures for 15 min following a 15-min preincubation with various antagonists (Sigma): pyridoxal-5'-phosphate-6-azophenyl-2,4-disulfonate (PPADS), suramin, or Reactive blue 2 (RB-2). The cell cultures were washed with PBS prior to the experimental treatment.

2.6. Release of LDH

Protein content and LDH activity were determined according to El-Ani et al. [21]. Briefly, 25 μl supernatant was transferred into a 96-well dish, and the LDH activities were determined with an LDH-L kit (Sigma), as described by the manufacturer. The product of the enzyme was measured spectrometrically at 30 °C at a wavelength of 340 nm as described previously [19]. The results were expressed relative to the control (X-fold) in the same experiment. Each experiment was done in triplicate and was repeated at least three times.

2.7. Staining

2.7.1. Propidium iodide—The assay is based on vital binding of propidium iodide (5 μg/ml) to nuclei of cells whose plasma membranes have become permeable because of cell damage. The assay was performed according to Nieminen et al. [22]. For counter-staining we used Hoechst 33342 (10 μM), which stains the nuclei of all cells.

2.7.2. Lysosome staining by neutral red—Neutral red is a widely used marker of membrane-bound compartments with an acidic lumen (lysosomes and several other acidic compartments). Live cardiomyocytes were incubated for 30 min in PBS containing 4 $\mu\text{g/ml}$ neutral red (Molecular Probes).

2.7.3. Immunostaining—Cells were fixed in absolute methanol for 10 min, permeabilized with 0.1% Triton X-100 for 5 min, and blocked in 2% normal goat serum for 10 min. Anti-P2Y₂ or anti-P2Y₄ antibodies (Alomone Labs) were diluted in PBS to a final concentration of 1:100 and then incubated overnight at room temperature with the cells. As a reporter we used goat antirabbit fluorescein isothiocyanate (FITC) that was incubated for 30 min at room temperature.

2.7.4. Western blotting—Aliquots (~70 μg) from each protein sample were loaded on 11% SDS polyacrylamide gels and blotted onto nitrocellulose membranes. Filters were saturated with Tris-buffered saline in 10% milk for 1 h at room temperature to avoid non-specific binding of the primary antibody and incubated overnight at 4 °C with anti-P2Y₂ (1:200) and anti-P2Y₄ (1:300) antibodies. Each P2Y receptor was also tested in the presence of neutralizing peptides (ratio 1:1 between peptide and antiserum). Blots were then washed in Tris-buffered saline (1 mM Tris-HCl, pH 8.0, 15 mM NaCl, 0.1% Tween X-100, final concentration), incubated for 1 h with antirabbit IgG coupled to FITC. Immunoreactions were analyzed with enhanced chemiluminescence.

2.8. Statistics

Results were expressed as mean \pm S.D. Data were analyzed by analysis of variance with application of a post hoc Tukey-Kremer test. Statistical significance was determined as * $P < 0.01$ and ** $P < 0.05$ in different experiments.

3. Results

3.1. Cardiomyocytes express UTP-responsive P2Y receptors

The presence of P2Y₂ and P2Y₄ receptors in cultured rat cardiomyocytes was demonstrated with immunofluorescent staining and Western immunoblot assay. Newborn rat cardiomyocytes exhibited P2Y₂ and P2Y₄ receptors on the cell surface, as seen from the fluorescence intensity level. The specificity of receptor immunostaining was indicated by lack of staining in the presence of competitive peptide antigens, derived from the receptor sequence. Anti-P2Y₂ or -P2Y₄ antibodies stained the whole cardiomyocyte membrane, but no staining was observed in fibroblasts that were present in the same culture dish (Fig. 1A and B). An immunoblot assay showed that anti-P2Y₂ antibodies detected four major protein bands of the predicted molecular weight at 42, 55, 68, and 84 kDa, and P2Y₄ receptors were identified by two protein bands, which were ~50 and ~80 kDa. These bands disappeared following preincubation of the antibodies with their competitive peptide antigens (Fig. 1C). These results demonstrated the existence of P2Y₂ and P2Y₄ receptors in neonatal cardiomyocytes.

3.2. Effect of UTP on cardiomyocytes subjected to hypoxia

To investigate the role of UTP in attenuation of myocyte injury during prolonged (120 min) hypoxia, cultured cardiomyocytes were incubated with various concentrations of UTP (3–50 μM) for 15 min prior to hypoxia. The pyrimidine (10 μM) did not cause any cell injury but elicited a significant attenuation of the cellular injury produced by the subsequent 120-min hypoxia, as measured by the level of LDH released from the cells (Fig. 2A). The decrease in LDH release suggested that UTP receptor activation delayed acute hypoxia-induced cardiomyocyte injury. For investigation of the time dependence of UTP in protecting the

cardiocytes, the cells were pretreated with 50 μM UTP for 1 h and then exposed to 2 h hypoxia after incubation in full medium for 15 min to 72 h. UTP protected the cells from hypoxia even when treated 48 h before hypoxia, as revealed by LDH release (Fig. 2B). These results suggest that UTP activates a long, persistent mechanism of protection (a second window of protection). On the other hand, the related derivatives uridine and UDP (50 μM) did not exhibit a protective effect on cardiomyocytes against hypoxia (Table 1). This ruled out the P2Y₆ receptor as the site of action of protective uracil nucleotides.

To verify whether the protective effect caused by UTP is mediated via P2 receptors, cardiomyocytes were treated with a P2 receptor antagonist, e.g. RB-2, PPADS, or suramin, before exposing them to 50 μM UTP and hypoxia. Treatment with suramin or PPADS, but not RB-2, inhibited the protective effect of UTP, as determined by LDH released to the medium (Table 1), indicating the involvement of P2Y₂ receptors and at least partly of P2Y₄ receptors in UTP-induced protection of cultured cardiomyocytes.

3.3. Effect of P2 agonists/antagonists on intracellular ATP levels during hypoxia

The protective effect caused by extracellular UTP was also demonstrated by protection of total ATP content after hypoxia. The results showed that the ATP level decreased dramatically after 2 h exposure to hypoxia (2.92 ± 0.17 nmol/mg protein compared with 20.12 ± 2.31 nmol/mg protein in normoxic cultures; Fig. 3). Pretreatment of cardiomyocytes with 50 μM UTP prevented the dramatic decrease of ATP levels (16.62 ± 4.62 nmol/mg protein) in cultures subjected to hypoxia. However, protection against ATP depletion did not occur when cells were pretreated with P2 receptor antagonist PPADS (1.84 ± 1.31 nmol/mg protein) or suramin (2.56 ± 0.87 nmol/mg protein) before exposure to UTP, indicating that the protective effect of UTP is mediated via P2 receptors.

The protective effect of UTP was also demonstrated through cardiomyocyte morphology. Following hypoxia the cells were fixed and stained with hematoxylin and eosin, which showed typical irreversible oncotic damage of cardiomyocytes: vacuoles and disorder of the myofilaments, pyknotic nuclei, and edematous areas in the cytoplasm and around the nucleus. In addition, hypoxic conditions increased the accumulation of the lysosomotropic vital dye neutral red in cytoplasmic granules and around the nucleus and increased the size of the lysosomes and the intensity of their color (Fig. 4). The damage to culture cells treated with UTP before hypoxia was greatly reduced. Cell loss (percentage of cell death) was presented as the number of dead cells (propidium iodide stained) as a percentage of the total number of cells (Hoechst 33341 stained). After 120 min of hypoxia cell loss was $40\% \pm 5\%$. Activation of the UTP receptors attenuated cell loss caused by hypoxia to $18\% \pm 2\%$; control untreated cells had $3.1\% \pm 0.2\%$ cell loss.

The contribution of the mitochondrial K_{ATP} channel to the protective effects of UTP was examined by application of a mK_{ATP} channel blocker, 5-hydroxydecanoic acid (5-HD; 200 μM), 15 min before treatment with UTP and hypoxia. The presence of 5-HD did not alter the protective effects of UTP, as revealed by LDH release to the medium (Table 1). These findings indicate that UTP exerts its protective effect via a pathway bypassing the mitochondrial K_{ATP} channel.

3.4. Effect of UTP receptor activation on intracellular [Ca²⁺]_i

[Ca²⁺]_i levels were determined by using indo-1 as a fluorescent probe. Treatment with 10 μM UTP induced transient accelerations of the beating rate and a transient elevation of [Ca²⁺]_i baseline, which lasted 30–40 s, and finally restored the normal beating activity (Fig. 5A). Application of PPADS (10 μM) or RB-2 (50 μM) prevented [Ca²⁺]_i elevation (Fig. 5B and C). Suramin (300 μM), which acts as an antagonist of P2Y₂ receptors among other P2

subtypes, did not prevent $[Ca^{2+}]_i$ elevation following activation of the UTP receptors (Fig. 5D). A possible pathway of UTP receptor signaling leading to an increase in $[Ca^{2+}]_i$ is activation of phospholipase C (PLC), which mediates inositol 1,4,5-trisphosphate (IP_3) production and calcium release from IP_3 receptors [23]. Application of (1-(6-((17 β -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) (U73122; 2 μ M an inhibitor of PLC activity) or 2-aminoethoxydiphenylborane (2APB), an IP_3 receptor inhibitor (50 μ M) abolished Ca^{2+} elevation after activation of UTP receptors (Fig. 6).

3.5. Effect of UTP on $[Ca^{2+}]_i$ level during hypoxia

Continuous monitoring of $[Ca^{2+}]_i$ during hypoxia was accomplished with a specially designed chamber, where cells were protected from oxygen by a laminar counterflowing layer of the inert gas argon. The level of $[Ca^{2+}]_i$ began to be elevated ~10–12 min after the initiation of hypoxia, with the cessation of beating activity (Fig. 7A). When the cardiomyocytes were pretreated with UTP (50 μ M) for 15 min and then subjected to hypoxia, a delay in $[Ca^{2+}]_i$ elevation was observed, and spontaneous contractions lasted for 30–40 min after the initiation of hypoxia (Fig. 7B). Pretreatment with UTP 24 h before the hypoxia resulted in maintenance of spontaneous contractility even after 40 min of hypoxia (Fig. 7C).

4. Discussion

In this work we demonstrate that short-term activation of UTP receptors protects newborn rat cardiomyocytes against hypoxic damage and significantly reduces the cell death caused by hypoxia via activation of $P2Y_2$ and $P2Y_4$ receptors.

It was shown in rat cardiomyocytes that UTP, an alternate agonist to ATP at $P2Y_2$ purinergic receptors, is as effective as ATP in stimulating PLC, and – as with ATP – the response is G_q mediated [23,24]. The uridine nucleotide-responding receptor $P2Y_4$, which when cloned from rat heart [25] is equipotently activated by ATP and UTP, is coupled, in part, to $G_{i/o}$ [24,26]. The presence of $P2Y_2$ and $P2Y_4$ receptors was demonstrated in the human fetal heart [27], but in adult myocytes, $P2Y_4$ receptors could hardly be detected [28]. Therefore, it is important to establish the expression of $P2Y_2$ and $P2Y_4$ receptors in newborn rat cardiomyocytes by immunohistochemical methods and immunoblotting. As was found in this study, rat newborn cardiomyocytes abundantly express $P2Y_2$ receptors, and anti- $P2Y_2$ antibodies detected four major proteins, indicating heterogeneity of these receptors. Higher MW bands may reflect receptor dimerization. Expression of $P2Y_4$ receptors also was found in newborn rat cardiomyocytes, although less abundant and represented by two protein bands.

The mechanism of action by which UTP induces cardioprotection is not known. Recent studies on UTP signaling showed that these receptors are coupled to the IP_3 pathway, which causes Ca^{2+} elevation [29]. As our study shows, the application of UTP induces an immediate increase in $[Ca^{2+}]_i$ level. This increase is not abolished by suramin, antagonist to $P2Y_2$ but not to $P2Y_4$ receptors [30], indicating that the immediate Ca^{2+} response to UTP is mediated through $P2Y_4$ receptors. The observed Ca^{2+} response may be a mechanism of UTP-mediated contraction (i.e., $P2Y_4$ receptor-mediated contraction), but evidently this pathway of $[Ca^{2+}]_i$ elevation is not involved in acute myocyte protection from hypoxia, because other uridine derivatives (UDP, uridine), although causing a transient elevation of intracellular Ca^{2+} , do not protect the cells from hypoxia. These data are consistent with known effects of uridine derivatives on heart performance [12]. These results imply that in spite of its central physiological role in cardiac cells, $[Ca^{2+}]_i$ elevation is not one of the critical elements in the cell-signaling pathway required for UTP-mediated classical cardioprotection (first window of protection).

This study shows that activation of UTP receptors protects cultured newborn rat cardiomyocytes from damage induced by hypoxia. It appears that the P2Y₂ receptor triggers a cardioprotective response, although we cannot exclude a role of the P2Y₄ receptor, because selective antagonists for this receptor are still not available. P2Y₄ receptors have been reported to couple via pertussis toxin-sensitive G proteins, and as Oldenburg et al. wrote, "Virtually all G_i-coupled receptors present on the cardiomyocyte are capable of preconditioning the myocardium, even if their ligands (exogenous agonists) are not released during a PC protocol" [13].

The present study found that the mitochondrial ATP-sensitive potassium channel, the opening of which is considered as an important step in the anti-infarct effect of ischemic preconditioning, plays no role in protection induced through UTP receptor activation.

Arthur et al. showed that ATP causes a robust activation of PLC via activation of G_q in newborn rat cardiomyocytes [31] and would be expected to cause hypertrophic responses like those caused by other factors that activate G_q-coupled receptors, such as α-adrenergic agonists, endothelin, and angiotensin II during long-term exposure [24]. However, ATP was reported to inhibit hypertrophic responses [32]. On the contrary, UTP is as effective as ATP in stimulating PLC [33] and causes hypertrophic responses in rat cardiomyocytes [24]. As the present study shows, short-term exposure to UTP stimulates both classical protection and a long-term, persistent mechanism of protection (second window of protection). It was reported that activation of phosphoinositide-3-kinase (PI3K) leads to cell survival, cytoskeletal rearrangement, and Ca²⁺ signaling. Cardiac cells express several PI3Ks, and their activity, together with the tyrosine kinase, is required to mediate Ca²⁺ spiking of neonatal rat cardiomyocytes [34,35]. PI3Ks phosphorylate phosphatidylinositol 4,5-bisphosphate, which after hydrolysis by PLCs produces IP₃.

It was recently shown that P2Y receptor activation leads to IP₃ generation, which induces mitochondrial Ca²⁺ loading and indirectly depletes Ca²⁺ from the sarcoplasmic reticulum [34,35]. The mitochondria can accumulate and release large amounts of Ca²⁺. Increased mitochondrial Ca²⁺ activates respiratory enzymes and increased ATP production, but pathological states such as ischemia cause a significant decrease of the ATP-ADP ratio and massive Ca²⁺ entry into the mitochondrial matrix, leading to cell death. As this study shows, short-term activation of UTP receptors protects mitochondria from Ca²⁺ overload and maintains increased levels of ATP production. These data complemented recent findings of Belous et al. [36], which described mitochondrial P2Y₂-like receptors linking cytosolic UTP to mitochondrial calcium uptake. It was found that UTP strongly inhibits mitochondrial Ca²⁺ uptake, which may promote respiratory chain activity and ATP production.

The involvement of UTP receptors in mediating cardioprotection reflects biological redundancy in the life-saving signals of P2Y₂ and P2Y₄ pyrimidinoceptors. Therapeutic targeting of pyrimidinergic receptors for protection against ischemic myocardial damage may be more effective than targeting the purinergic receptors. The breakdown product of UTP, uridine, unlike adenosine, has limited ancillary pharmacologic effects [37]. ATP is degraded to adenine nucleotides and nucleosides, so that the response of cardiomyocytes should be the mixture of various effects of these multiple compounds [38]. Thus, UTP may be used in preference to ATP as a P2Y₂ and P2Y₄ receptor agonist, because it does not form cardiovascularly active metabolites such as adenosine.

Acknowledgments

This research was partially supported by the Horowitz Foundation at Bar-Ilan University and the Israel Ministry of Health. We are indebted to Ms. Avrille Goldreich for helping to prepare this manuscript and to Tova Zinman and Ahuva Isaac for their valuable technical assistance.

References

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986; 74:1124–36. [PubMed: 3769170]
2. Miki T, Miura T, Bungler R, Suzuki K, Sakamoto J, Shimamoto K. Ecto-5'-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. *Am J Physiol*. 1998; 275:H1329–37. [PubMed: 9746483]
3. Miura T, Ishimoto R, Sakamoto J, Tsuchida A, Suzuki K, Ogawa T, et al. Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor. *Basic Res Cardiol*. 1995; 90:240–6. [PubMed: 7575377]
4. Li Y, Kloner RA. The cardioprotective effects of ischemic preconditioning are not mediated by adenosine receptors in rat hearts. *Circulation*. 1993; 87:1642–8. [PubMed: 8491020]
5. Hu K, Nattel S. Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. *Circulation*. 1995; 92:2259–65. [PubMed: 7554210]
6. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. *Circ Res*. 1995; 77:611–21. [PubMed: 7641331]
7. Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. *Mol Cell Biochem*. 1998; 186:3–12. [PubMed: 9774179]
8. Ninomiya H, Otani H, Lu K, Uchiyama T, Kido M, Imamura H. Enhanced IPC by activation of pertussis toxin-sensitive and -insensitive G protein-coupled purinoceptors. *Am J Physiol Heart Circ Physiol*. 2002; 282:H1933–H1943. [PubMed: 11959661]
9. Burnstock, G. A basis for distinguishing two types of purinergic receptor. In: Bolis, L.; Straub, RW., editors. *Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach*. New York: Raven Press; 1978. p. 107-18.
10. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. *Cell Signal*. 2000; 12:351–60. [PubMed: 10889463]
11. Jacobson KA, Jarvis MF, Williams M. Purine and pyrimidine (P2) receptors as drug targets. *J Med Chem*. 2002; 45:4057–93. [PubMed: 12213051]
12. Eliseev VV, Rodionova OM, Saponov NS, Selizarova NO. The effect of uridine and uridine nucleotides on isolated rat heart performance in regional myocardial ischemia. *Patol Fiziol Eksp Ter*. 2002; 2:13–5. [PubMed: 12152421]
13. Oldenburg O, Cohen MV, Yellon DM, Downey JM. Mitochondrial K(ATP) channels: role in cardioprotection. *Cardiovasc Res*. 2002; 55:429–37. [PubMed: 12160940]
14. Abbracchio MP, Burnstock G. Purinergic signalling: pathophysiological roles. *Jpn J Pharmacol*. 1998; 78:113–45. [PubMed: 9829617]
15. Shneyvays V, Nawrath H, Jacobson KA, Shainberg A. Induction of apoptosis in cardiac myocytes by an A₃ adenosine receptor agonist. *Exp Cell Res*. 1998; 243:383–97. [PubMed: 9743598]
16. Safran N, Shneyvays V, Balas N, Jacobson KA, Shainberg A. Cardioprotective effects of adenosine A₁ and A₃ receptor activation during hypoxia in isolated rat cardiac myocytes. *Mol Cell Biochem*. 2001; 217:143–52. [PubMed: 11269659]
17. Shneyvays V, Mamedova L, Zinman T, Jacobson K, Shainberg A. Activation of A₃ adenosine receptor protects against doxorubicin-induced cardiotoxicity. *J Mol Cell Cardiol*. 2001; 33:1249–61. [PubMed: 11444927]
18. Fixler D, Tirosh R, Zinman T, Shainberg A, Deutsch M. Differential aspects in ratio measurements of [Ca²⁺]_i relaxation in cardiomyocyte contraction following various drug treatments. *Cell Calcium*. 2002; 31:279–87. [PubMed: 12098217]
19. Shneyvays V, Safran N, Halili-Rutman I, Shainberg A. Insights into adenosine A₁ and A₃ receptors function: cardiotoxicity and cardioprotection. *Drug Dev Res*. 2000; 50:324–37.
20. Stern MD, Silverman HS, Houser SR, Josephson RA, Capogrossi MC, Nichols CG, et al. Anoxic contractile failure in rat heart myocytes is caused by failure of intracellular calcium release due to alteration of the action potential. *Proc Natl Acad Sci USA*. 1988; 85:6954–8. [PubMed: 3413129]

21. El-Ani D, Jacobson KA, Shainberg A. Characterization of adenosine receptors in intact cultured heart cells. *Biochem Pharmacol.* 1994; 48:727–35. [PubMed: 8080445]
22. Nieminen AL, Gores GJ, Bond JM, Imberti R, Herman B, Lemasters JJ. A novel cytotoxicity screening assay using a multiwell fluorescence scanner. *Toxicol Appl Pharmacol.* 1992; 115:147–55. [PubMed: 1641848]
23. Puceat M, Vassort G. Purinergic stimulation of rat cardiomyocytes induces tyrosine phosphorylation and membrane association of phospholipase C gamma: a major mechanism for InsP3 generation. *Biochem J.* 1996; 318:723–8. [PubMed: 8809068]
24. Pham TM, Morris JB, Arthur JF, Post GR, Brown JH, Woodcock EA. UTP but not ATP causes hypertrophic growth in neonatal rat cardiomyocytes. *J Mol Cell Cardiol.* 2003; 35:287–92. [PubMed: 12676543]
25. Bogdanov YD, Wildman SS, Clements MP, King BF, Burnstock G. Molecular cloning and characterization of rat P2Y₄ nucleotide receptor. *Br J Pharmacol.* 1998; 124:428–30. [PubMed: 9647463]
26. Filippov AK, Simon J, Barnard EA, Brown DA. Coupling of the nucleotide P2Y₄ receptor to neuronal ion channels. *Br J Pharmacol.* 2003; 138:400–6. [PubMed: 12540532]
27. Bogdanov Y, Rubino A, Burnstock G. Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. *Life Sci.* 1998; 62:697–703. [PubMed: 9489506]
28. Hou M, Malmisjo M, Moller S, Pantev E, Bergdahl A, Zhao XH, et al. Increase in cardiac P2X₁- and P2Y₂-receptor mRNA levels in congestive heart failure. *Life Sci.* 1999; 65:1195–206. [PubMed: 10503935]
29. Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. *Annu Rev Pharmacol Toxicol.* 1995; 35:541–79. [PubMed: 7598506]
30. von Kügelgen I, Wetter A. Molecular pharmacology of P2Y-receptors. *Naunyn Schmiedebergs Arch Pharmacol.* 2000; 362:310–23. [PubMed: 11111826]
31. Arthur JF, Matkovich SJ, Mitchell CJ, Biden TJ, Woodcock EA. Evidence for selective coupling of alpha 1-adrenergic receptors to phospholipase C-beta 1 in rat neonatal cardiomyocytes. *J Biol Chem.* 2001; 276:37341–6. [PubMed: 11489909]
32. Zheng JS, Boluyt MO, Long X, O'Neill L, Lakatta EG, Crow MT. Extracellular ATP inhibits adrenergic agonist-induced hypertrophy of neonatal cardiac myocytes. *Circ Res.* 1996; 78:525–35. [PubMed: 8635209]
33. Podrasky E, Xu D, Liang BT. A novel phospholipase C- and cAMP-independent positive inotropic mechanism via a P2 purinoceptor. *Am J Physiol.* 1997; 273:2380–7.
34. Jaconi M, Bony C, Richards SM, Terzic A, Arnaudeau S, Vassort G, et al. Inositol 1,4,5-trisphosphate directs Ca²⁺ flow between mitochondria and the endoplasmic/sarcoplasmic reticulum: a role in regulating cardiac autonomic Ca²⁺ spiking. *Mol Biol Cell.* 2000; 11:1845–58. [PubMed: 10793156]
35. Bony C, Roche S, Shuichi U, Sasaki T, Crackower MA, Penninger J, et al. A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca²⁺ oscillations in cardiac cells. *J Cell Biol.* 2001; 152:717–28. [PubMed: 11266463]
36. Belous A, Wakata A, Knox CD, Nicoud IB, Pierce J, Anderson CD, et al. Mitochondrial P2Y-like receptors link cytosolic adenosine nucleotides to mitochondrial calcium uptake. *J Cell Biochem.* 2004; 92:1062–73. [PubMed: 15258927]
37. Vassort G. Adenosine 5'-triphosphate: a P2-purinergic agonist in the myocardium. *Physiol Rev.* 2001; 81:767–806. [PubMed: 11274344]
38. Williams M, Jarvis MF. Purinergic and pyrimidineric receptors as potential drug targets. *Biochem Pharmacol.* 2000; 59:1173–85. [PubMed: 10736418]

Abbreviations

2APB	2-aminoethoxydiphenylborane
ATP	adenosine 5'-triphosphate

FITC	fluorescein isothiocyanate
5-HD	5-hydroxydecanoic acid
IP₃	inositol 1,4,5-trisphosphate
LDH	lactate dehydrogenase
PBS	phosphate buffered saline
PC	preconditioning
PI3K	phosphoinositide-3-kinase
PLC	phospholipase C
PKC	protein kinase C
PPADS	pyridoxal-5'-phosphate-6-azophenyl-2,4-disulfonate
RB-2	Reactive blue 2
U73122	(1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)-hexyl)-1H-pyrrole-2,5-dione)
UDP	uridine-5'-diphosphate
UTP	uridine-5'-triphosphate




Fig. 1. Determination of P2Y receptors in cardiomyocytes by immunofluorescent staining and immunoblotting. Cardiomyocytes were fixed in methanol, permeabilized with 1% Triton X-100, blocked and incubated in the presence of antibodies against P2Y₂ (A) or P2Y₄ (B) receptors. For detection of the bound antibodies, cells were incubated with goat antirabbit FITC (green) following counterstaining with propidium iodide (red). Bars = 10 μm. Proteins isolated from rat cardiomyocyte homogenates were subjected to SDS-PAGE on an 11% acrylamide gel and transferred onto a nitrocellulose membrane. Filters were probed with the indicated P2Y antibodies simultaneously with the neutralizing peptide (np). Protein bands were detected with a secondary antibody coupled to peroxidase by enhanced chemiluminescence (C).




Fig. 2. Concentration- and time-dependent effect of UTP on cardiomyocytes subjected to hypoxia. Six-day-old cardiomyocytes were treated for 15 min with various concentrations of UTP (3–50 μ M). The cells were then washed twice and subjected to hypoxia for 2 h in glucose-free PBS, at 37 $^{\circ}$ C. The amount of LDH released to the medium was determined and compared to the total activity of control homogenate (100%; A). Cardiomyocytes were treated with 50 μ M UTP for 15 min or 24 h before hypoxia. Other groups of cells were incubated with 50 μ M UTP for 1 h, washed and replaced with normal medium and then subjected to hypoxia 24, 48, or 72 h subsequent to the treatment with UTP (B). Data are means of at least three replicates in five separate experiments \pm S.D. * P < 0.01, ** P < 0.05 compared with hypoxia.




Fig. 3. Effect of P2 agonists/antagonists on intracellular ATP levels after hypoxia. Cardiomyocytes were treated for 15 min with P2 antagonist PPADS (10 μ M), RB-2 (50 μ M), or suramin (300 μ M) before application of UTP (50 μ M). Intracellular ATP levels after 2 h hypoxia were measured as described. Data are means of at least three replicates in six separate experiments \pm S.D. * $P < 0.01$ compared with hypoxia.




Fig. 4. Effect of UTP on cardiomyocyte morphology in hypoxic conditions. Six-day-old cultured cardiomyocytes under normoxic conditions were subjected to 2 h hypoxic environment or pretreated with 50 μ M UTP and then subjected to hypoxia. One group of these cells was stained with propidium iodide (red), which marks damaged cells, and with Hoechst 33342 (blue), which stains live-cell nuclei (first column). A second group of cells was stained with hematoxylin and eosin (second column). A third group of cells was stained with neutral red, which stains lysosomes (third column). The results shown are representative of six experiments. Bars = 10 μ m.




Fig. 5. Effect of antagonists on the $[Ca^{2+}]_i$ response. Indo-1-loaded cardiomyocytes were pretreated with UTP (A) or with P2 antagonist PPADS (10 μ M, B), RB-2 (50 μ M, C), or suramin (300 μ M, D) before application of UTP (50 μ M). The fluorescence ratio of 410:490 nm, which is proportional to changes in Ca^{2+} levels, is demonstrated. One experiment shown is representative of seven.




Fig. 6. Effect of UTP on $[Ca^{2+}]_i$ elevation in Ca^{2+} -free medium or in the presence of PLC inhibitor. Indo-1-loaded cardiomyocytes were exposed to 2 μ M U73122, a PLC inhibitor (A), or to 2APB an IP_3 receptor inhibitor (50 μ M) (B) 15 min before UTP (50 μ M) application. The changes in Ca^{2+} levels are demonstrated. One experiment shown is representative of five.




Fig. 7.

Effect of UTP on $[Ca^{2+}]_i$ accumulation during hypoxia. Cardiomyocytes received UTP for 15 min just before hypoxia (B) or 24 h before hypoxia (C). Calcium was monitored during hypoxia with indo-1. The fluorescence ratio of 410:490 is demonstrated. Each recording was done for 10 s at times 0, 20, 40, and 60 min after the initiation of the hypoxia. The effect of hypoxia alone is also shown (A). One experiment shown is representative of five.

Table 1

Effect of uracil derivatives or P2 receptors antagonists on cardiomyocytes subjected to hypoxia

Treatment	LDH release (%)
Normoxia	4.2 ± 0.6
Hyp	40 ± 2.4
Hyp + UTP	10 ± 1.6*
Hyp + uridine	29 ± 2.5
Hyp + UDP	36 ± 2.6
Hyp + 5-HD	37 ± 0.6
Hyp + UTP + 5-HD	12 ± 1.6*
Hyp + UTP + PPADS	32 ± 3.6
Hyp + UTP + suramin	25 ± 3.5
Hyp + UTP + RB-2	11 ± 0.8*

Cardiomyocytes were treated with 50 μ M uridine, UDP, or UTP or with P2 receptor antagonist PPADS (10 μ M), RB-2 (50 μ M), or suramin (300 μ M) or with 5-HD, a mitochondrial K_{ATP} channel inhibitor (300 μ M), for 15 min before hypoxia. The cells were then washed twice and subjected to hypoxia for 2 h in glucose-free PBS, at 37 °C. The amount of LDH released to the medium was determined and compared to the total activity of control homogenate (100%). Data are means of at least three replicates in three separate experiments \pm S.D.

* $P < 0.01$ compared with hypoxia.